Upper Aerodigestive Tract Carcinoma Surveillance Counterpoint: Japan

  • Torahiko NakashimaEmail author
  • Ryuji Yasumatsu
  • Shizuo Komune
Part of the Current Clinical Oncology book series (CCO)


In Japan, head and neck cancer comprises 5–6 % of all cancer patients. The major sites of head and neck cancer are oral cavity, oropharynx, hypopharynx, and larynx. Squamous cell carcinoma is the most common histological type and the age-standardized incidence rates for tongue, oropharyngeal, hypopharyngeal cancer are now steadily increasing [1]. Age-standardized mortality rates for oral and pharyngeal cancer had been low compared to the US, UK, France, and Italy, but are now both increasing [2]. The age-standardized mortality rate for laryngeal cancer in Japan is also lower than in other countries; it is decreasing, especially in females [3]. The incidence of maxillary sinus cancer had been high compared to the western countries (comprising approximately 7 % of head and neck cancers in Japan). This is related to the high incidence of chronic maxillary sinusitis. However, due to improved nutrition and the decreasing incidence of maxillary sinusitis, the incidence of maxillary sinus cancer is decreasing.


Modalities Cancer Japan Cancer rates Treatment 


  1. 1.
    Ioka A, Tsukuma H, Ajiki W, Oshima A. Trends in head and neck cancer incidence in Japan during 1965-1999. Jpn J Clin Oncol. 2005;35:45–7.PubMedCrossRefGoogle Scholar
  2. 2.
    Tanaka S, Sobue T. Comparison of oral and pharyngeal cancer mortality in five countries: France, Italy, Japan, UK and USA from the WHO Mortality Database (1960-2000). Jpn J Clin Oncol. 2005;35:488–91.PubMedCrossRefGoogle Scholar
  3. 3.
    Sano H, Hamashima C. Comparison of laryngeal cancer mortality in five countries: France, Italy, Japan, UK and USA from the WHO mortality database (1960-2000). Jpn J Clin Oncol. 2005;35:626–9.PubMedCrossRefGoogle Scholar
  4. 4.
    Bold B, Piao Y, Murata Y, Kishino M, Shibuya H. Usefulness of PET/CT for detecting a second primary cancer after treatment for squamous cell carcinoma of the head and neck. Clin Nucl Med. 2008;33:831–3.PubMedCrossRefGoogle Scholar
  5. 5.
    Wollenberg B, Jan V, Schmit UM, Hofmann K, Stieber P, Fateh-Moghadam A. CYFRA 21-1 is not superior to SCC antigen and CEA in head and neck squamous cell cancer. Anticancer Res. 1996;16:3117–24.PubMedGoogle Scholar
  6. 6.
    Kandiloros D, Eleftheriadou A, Chalastras T, Kyriou L, Yiotakis I, Ferekidis E. Prospective study of a panel of tumor markers as prognostic factors in patients with squamous cell carcinoma of head and neck. Med Oncol. 2006;23:463–70.PubMedCrossRefGoogle Scholar
  7. 7.
    Matsubara N, Umezaki T, Adachi K, Tomita E, Matsuyama K, Nakagawa T, et al. Multidimensional voice evaluation in pretreatment glottic carcinoma. Folia Phoniatr Logop. 2005;57:173–80.PubMedCrossRefGoogle Scholar
  8. 8.
    Rogers JW, Greven KM, McGuirt WF, Keyes Jr JW, Williams 3rd DW, Watson NE, et al. Can post-RT neck dissection be omitted for patients with head-and-neck cancer who have a negative PET scan after definitive radiation therapy? Int J Radiat Oncol Biol Phys. 2004;58:694–7.PubMedCrossRefGoogle Scholar
  9. 9.
    Pellitteri PK, Ferlito A, Rinaldo A, Shah JP, Weber RS, Lowry J, et al. Planned neck dissection following chemoradiotherapy for advanced head and neck cancer: is it necessary for all? Head Neck. 2006;28:166–75.PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press 2013

Authors and Affiliations

  • Torahiko Nakashima
    • 1
    Email author
  • Ryuji Yasumatsu
    • 1
  • Shizuo Komune
    • 1
  1. 1.Department of OtorhinolaryngologyGraduate School of Medical Sciences, Kyushu UniversityFukuokaJapan

Personalised recommendations